Jayson B. Field
Advanced in Sertoli-Leydig Cell Tumor

Dr. Jayson B. Field

Oncology
633 South Boulevard East, 
Rochester Hills, MI 
On Staff At
Accepting New Patients
28 Years of Experience
Advanced in Sertoli-Leydig Cell Tumor
633 South Boulevard East, 
Rochester Hills, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jayson Field is an Oncologist in Rochester Hills, Michigan. Dr. Field has been practicing medicine for over 28 years and is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Testicular Yolk Sac Tumor, and Ovarian Carcinosarcoma. Dr. Field is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Sertoli-Leydig Cell Tumor.

Graduate Institution
Wayne State University School Of Medicine, 1998
Residency
Wayne State University School of Medicine
Specialties
Oncology
Licenses
Obstetrics & Gynecology in MI
Board Certifications
American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology
Fellowships
University of Texas Medical Branch Hospitals
Hospital Affiliations
Corewell Health Beaumont Troy Hospital
Corewell Health William Beaumont University Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS

Locations

Michigan Gynecologic Oncology and Surgical Care
633 South Boulevard East, Rochester Hills, MI 48307

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 3 Less Clinical Trials

4 Total Publications

Sequencing of Adjuvant Chemoradiation for Advanced Stage Endometrial Cancer: Outcomes and Toxicity Profiles.
Sequencing of Adjuvant Chemoradiation for Advanced Stage Endometrial Cancer: Outcomes and Toxicity Profiles.
Journal: American journal of clinical oncology
Published: August 10, 2020
Similar Doctors
Barry P. Rosen
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Barry P. Rosen
Oncology | Surgical Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Barry P. Rosen
Oncology | Surgical Oncology

Corewell Health Dearborn Hospital Gynecologic Oncology

18101 Oakwood Boulevard, First Floor Cancer Center, 
Dearborn, MI 
 (25.9 miles away)
313-436-2898
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Barry Rosen is an Oncologist and a Surgical Oncologist in Dearborn, Michigan. Dr. Rosen has been practicing medicine for over 49 years and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Salpingo-Oophorectomy, and Bladder Reconstruction. Dr. Rosen is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. Jeffrey H. Margolis
Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Jeffrey H. Margolis
Oncology

Oakland Medical Group - Division Of Clinical Hematology & Medical Oncology - Royal Oak

3577 West 13 Mile Road, Suite 310, 
Royal Oak, MI 
 (10.4 miles away)
248-551-2446
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Margolis is an Oncologist in Royal Oak, Michigan. Dr. Margolis has been practicing medicine for over 33 years and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Margolis is currently accepting new patients.

Haider Mahdi
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Haider Mahdi
Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Haider Mahdi
Oncology

Amal Gynecologic Oncology Clinic

2300 Haggerty Road, 
West Bloomfield, MI 
 (17.5 miles away)
313-300-1492
Experience:
22+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haider Mahdi is an Oncologist in West Bloomfield, Michigan. Dr. Mahdi has been practicing medicine for over 22 years and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Lymphadenectomy, and Endoscopy. Dr. Mahdi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Field's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile